| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 520 | 70,810 | 19,790 | 44,950 | 16,980 |
| Sales Growth | -99.27% | +257.81% | -55.97% | +164.72% | +405.36% |
| Net Income | -152,100 | -59,040 | -95,540 | -45,000 | -43,330 |
| Net Income Growth | -157.62% | +38.20% | -112.31% | -3.85% | -81.83% |
Morphic Holding Inc (MORF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Morphic Holding Inc. is a biopharmaceutical company. It focuses on the discovery and development of oral small-molecule integrin therapeutics for autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer. Morphic Holding Inc. is based in Waltham, Massachusetts.
Fiscal Year End Date: 12/31